17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of CAPLYTA® (lumateperone) Phase 3 data evaluates the impact on sexual function in MDD, reinforcing potential to reset treatment expectations European Union and United Kingdom sub-group analyses of Phase 3 data evaluate efficacy of adjunctive seltorexant compared to adjunctive quetiapine XR in MDD with i

WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- In 2024, the U.S. once again ranked as the largest supplier to UN agencies, securing $2.13 billion in contracts. That's more than the U.S. pays in dues to the UN and accounts for nearly one in ten UN contracts worldwide – a steady share that keeps jobs and dollars flowing back into towns and cities across the country. "These aren't abstract numbers," said Peter Yeo, President of the Better World Campaign. "They translate into real work for real American

Bristol Myers Squibb is delving further into cell therapies with the $1.5 billion cash purchase of Orbital Therapeutics, the New Jersey pharma said Friday morning. The move positions BMS in the in vivo CAR-T space following similar acquisitions from its big pharma peers earlier this year. AbbVie bought Capstan , AstraZeneca acquired EsoBiotec and Gilead’s Kite snagged Interius BioTherapeutics . Multiple other startups, such as Umoja Biopharma , are competing here as well. Orbital came out of ste

Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a major Cardiology Congress Via Less Invasive Approach, more Cardiologists could implant out-patient Additional studies expanding indications and level of evidence are planned next ZUG, Switzerland, Oct. 10, 2025 /PRNewswire/ -- Berlin Heals Holding AG, a leading clinical-stage medical device company focused on revolutionizing the care of Heart Failure with a first of it

Samsara BioCapital, an investment firm that has backed dozens of life sciences companies, is aiming to raise up to $200 million for its opportunity fund, according to an SEC filing . The Palo Alto, CA-based firm has reeled in about $98 million so far from 19 investors, according to the filing on Friday. Opportunity funds are generally used to support an investment firm’s existing portfolio companies. Many private biotech investors have concentrated their bets on fewer companies during the curren

TOKYO, Oct. 10, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced today that it has completed data collection for the primary endpoint in the Phase III clinical trial of sparsentan (development code: RE-021) for IgA nephropathy in Japan. The primary endpoint evaluated was the urine protein creatinine ratio (24-hour urine collection) at 36 weeks and data have now been collected for all eligible patients. Renalys will proceed with analyses of efficacy an

AviadoBio has gained an option for exclusive, ex-China rights to UgeneX's clinical-stage AAV-based gene therapy UGX-202 for retinitis pigmentosa (RP). Under the deal, announced Thursday, UgeneX stands to receive up to $413 million comprising upfront payments and R&D and sales milestones, if AviadoBio exercises its option for development and commercial rights to UGX-202. UgeneX is also eligible for royalties on net sales.In addition to RP, UGX-202 is in development for multiple other inherited re

Ono Pharmaceutical on Thursday said its Bristol Myers Squibb-partnered oral EP4 antagonist ONO-4578, in combination with the latter’s PD-1 inhibitor Opdivo (nivolumab) and chemotherapy, hit the mark in a mid-stage study, demonstrating a progression-free survival (PFS) benefit in first-line advanced HER2-negative gastric cancer. According to Ono, ONO-4578 is designed to block the PGE2 pathway used by cancer cells to suppress immune responses, with the aim of restoring anti-tumour immunity. Combin

10 October 2025 marie.peytavy CTIBIOTECH has been selected by SATT AxLR and CILCARE to develop the OrgaEar project, a disruptive innovation in hearing disorders research. Hearing disorders are a growing public health crisis. The development of innovative therapeutic solutions is an urgent strategic priority. Facilitating a highly advanced non-animal New Approach Methods NAMs alternative in the hearing disorders sector, CTIBIOTECH strengthens its position at the forefront of a cell-based bioassay

– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions in HSV-2 shedding rate, high viral load shedding rate and genital lesion rate observed in the cohort evaluating 350 mg weekly oral dose compared to placebo – – Interim data evaluating a monthly dosing regimen of ABI-5366 and weekly dosing for second HSV helicase-primase inhibitor candidate ABI-1179 exp